Workflow
首药控股: 首药控股(北京)股份有限公司2024年年度股东大会会议资料

Meeting Guidelines - The company has established meeting guidelines to ensure the rights of all shareholders are protected during the shareholder meeting [1][2] - Only authorized personnel, including shareholders, their agents, directors, supervisors, senior management, and invited guests, are allowed to enter the meeting venue [1][2] - Shareholders must arrive 30 minutes before the meeting to complete registration and present identification [1][2] Shareholder Rights and Conduct - Shareholders and their agents have the right to speak, consult, and vote during the meeting, but must adhere to the rules to maintain order [2][3] - Any questions or speeches must be registered in advance and should be concise, limited to 5 minutes [2][3] - The meeting host has the authority to refuse or stop any disruptive behavior [2][3] Voting Procedures - Voting will be conducted through a named ballot system, where each share represents one vote [3] - Votes can be cast as "agree," "disagree," or "abstain," and improperly filled ballots will be considered abstentions [3] - The meeting will include both on-site and online voting, with results announced after the voting period [3] Meeting Agenda - The meeting is scheduled for May 20, 2025, at 10:00 AM in Beijing [5] - The agenda includes registration, reports from independent directors, shareholder speeches, and voting on various proposals [5][6] - Key proposals include the approval of the 2024 annual report and the board's work report [5][6] Financial Overview - The company reported a significant decrease in revenue for 2024, with total revenue of approximately 3.94 billion yuan, a decline of 24.61% compared to 2023 [27] - The net profit attributable to shareholders was approximately -211.94 million yuan, indicating a loss compared to previous years [27] Future Plans - The company plans to invest approximately 230 million yuan in research and development in 2025, an increase of 8.14% from 2024 [19][17] - The focus will be on advancing clinical trials for key products and expanding the drug pipeline [19][17] - The company aims to enhance its market strategies and strengthen its sales team to improve competitiveness [18][19]